An ideal way to keep informed of the dealmaking activity of 50 of the top pharmaceutical companies.
Partneringdesk™ Deals Briefings provide a comprehensive summary of the deals and alliances announced by 50 of the top pharmaceutical and biotechnology companies and subsidiaries, each covering the period January 2001 to March 2006.Buying Partneringdesk Deals Briefings
The reports include a brief company profile, a financial data and deals overview, and a detailed listing of the company’s deals and alliances.
Information breakdown for every deal entry includes:
- Date of announcement
- Partners
- Deal type
- Industrial sector
- Therapy sector
- Stage of development (where disclosed)
- Deal exclusivity (where disclosed)
- Total deals value (where disclosed)
- Financials (where disclosed)
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies.
Other selected research from the 'Business Development' category:
Partneringdesk Tanabe Seiyaku Co., Ltd. & Company Deals Briefing
Comprehensive summary of the last 5 years of deal-making by the industry’s top 50 pharmaceutical and biotech companies. Learn More
Mergers, acquisitions and licensing to continue drive industry growth
Inorganic growth strategies have played a significant role in the pharmaceutical industry over recent years. While acquisitions and licensing look set to continue to drive growth in the future, increasing competition for the best deal and best partner will require companies to review a broader set of potential targets and search for earlier stage licensing opportunities Learn More
Other selected research from the 'Companies' category:
Eli Lilly: PharmaVitae Profile 2005
This company analysis examines the current position and future outlook for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides updated quantitative and qualitative information. Learn More
Merck & Co. Inc: PharmaVitae Profile 2008
This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. Learn More